SYNAPTIC PHARMACOLOGY OF THE BASAL GANGLIA

Project: Research project

Description

The purpose of the proposal is to investigate the ability of dopamine, adenosine and 5-hydroxytryptamine to regulate GABA release from striatal nerve terminals in the globus pallidus and substantia nigra pars reticulate. Experiments will use patch pipettes in voltage clamp to record whole cell membrane currents in GP and SNR neurons in rat brain slices. Biopolar stimulation electrodes will be placed in the brain slice to evoke currents produced by release of GABA from afferent nerve terminals. The hypothesis is that dopamine acts at presynaptic D1 receptors to increase the release of GABA from nerve terminals in the SNR, whereas stimulation of adenosine A1 and 5-HT1B receptors reduce GABA release. In contrast, the potentially opposing influences of presynaptic dopamine D1 and adenosine A2A receptor-stimulation on GABA release from nerve terminals in the GP will be investigated. In addition, the hypothesis that the straitonigral pathway selectively releases GABA onto GABAB receptors on dopamine neurons in the sustantia nigra zona compacta will be tested.
StatusFinished
Effective start/end date8/15/975/31/01

Funding

  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Basal Ganglia
gamma-Aminobutyric Acid
Pharmacology
Dopamine
Adenosine
Receptor, Serotonin, 5-HT1B
Adenosine A2A Receptors
Presynaptic Receptors
Corpus Striatum
Globus Pallidus
Dopaminergic Neurons
Herpes Zoster
Brain
Substantia Nigra
Serotonin
Electrodes
Cell Membrane
Neurons

ASJC

  • Medicine(all)
  • Neuroscience(all)